7/06/04

EXPRESS MAIL NO: EV 456 933 485 US

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of:	Huang *et al.*	Confirmation No.:	4803
Serial No.:	10/612,604	Art Unit:	1648
Filed:	July 1, 2003	Examiner:	Stacy Brown Chen
For:	COMPOSITIONS AND METHODS FOR DETERMINING THE REPLICATION CAPACITY OF A PATHOGENIC VIRUS	Attorney Docket No.:	11068-014-999

INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

In accordance with the duty of disclosure provisions of 37 C.F.R. §1.56, there is hereby provided certain information which the Examiner may consider material to the examination of the subject U.S. patent application. It is requested that the Examiner make this information of record if it is deemed material to the examination of the application.

1. Enclosures accompanying this Information Disclosure Statement are:

1a. ☒ A list of all patents, publications, applications, or other information submitted for consideration by the office.

1b. A legible copy of :

☒ Each U.S. patent application publication and U.S. and foreign patent;

☒ Each publication or that portion which caused it to be listed on the PTO-1449;

☐ For each cited pending U.S. application, the application specification including the claims, and any drawing of the application, or portion of the application which caused it to be listed on the PTO-1449 including any claims directed to that portion;

☐ all other information or portion which caused it to be listed on the PTO-1449.

1c. ☒ An English language copy of search report(s) from a counterpart foreign application or PCT International Search Report.

1d. ☐ Explanations of relevancy (ATTACHMENT 1(d), hereto) or English language abstracts of the non-English language publications.

2. ☒ This Information Disclosure Statement is filed under 37 C.F.R. §1.97(b):
☐ Within three months of the filing date of a national application other than a continued prosecution application under §1.53(d);

☐ Within three months of the date of entry of the national stage as set forth in §1.491 in an international application;

☒ Before the mailing of the first Office action on the merits;

☐ Before the mailing of a first Office action after the filing of a request for continued examination under §1.114.

3. ☐ This Information Disclosure Statement is filed under 37 C.F.R. §1.97(c) after the period specified in 37 C.F.R §1.97(b), but before the mailing date of any of a final action under 37 C.F.R. §1.113, a notice of allowance under 37 C.F.R. §1.311 or an action that otherwise closes prosecution in the application.

(Check either Item 3a or 3b)

3a. ☐ The Certification Statement in Item 5 below is applicable. Accordingly, no fee is required.

3b. ☐ The $180.00 fee set forth in 37 C.F.R. §1.17(p) in accordance with 37 C.F.R. §1.97(c) is:
☐ enclosed
☐ to be charged to Jones Day Deposit Account No. 503013.

(Item 3b to be checked if any reference known for more than 3 months)

4. ☐ This Information Disclosure Statement is filed under 37 C.F.R. §1.97(d) after the period specified in 37 C.F.R. §1.97(c), but on or before the date of payment of the issue fee.

The $180.00 fee set forth in 37 C.F.R. §1.17(p) is:
☐ enclosed.
☐ to be charged to Jones Day Deposit Account No. 503013.

The Certification Statement in Item 5 below is applicable.

5. ☐ Certification Statement (applicable if Item 3a or Item 4 is checked)

(Check either Item 5a or 5b)

5a. ☐ In accordance with 37 C.F.R. §1.97(e)(1), it is certified that each item of information contained in this Information Disclosure Statement was first cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this Information Disclosure Statement.

5b. ☐ In accordance with 37 C.F.R. §1.97(e)(2), it is certified that no item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application and, to the knowledge of the undersigned after making reasonable inquiry, was known by any individual designated in 37 C.F.R. §1.56(c) more than three months prior to the filing of this Information Disclosure Statement.

6. ☐ This application is a continuation application under 37 C.F.R. §1.60 or §1.53(b) or (d).

(Check appropriate Items 6a, 6b and/or 6c)

6a. ☐ A Petition to Withdraw from issue under 37 C.F.R. §1.313(b)(5) is concurrently filed herewith.

6b. ☐ Copies of publications listed on Form PTO-1449 from prior application Serial No. , filed on , of which this application claims priority under 35

U.S.C. §120, are not being submitted pursuant to 37 C.F.R. §1.98(d).

6c. ☐ Copies of the publications listed on Form PTO-1449 were not previously cited in prior application Serial No. , filed on , and are provided herewith.

7. ☐ This is a Supplemental Information Disclosure Statement. (Check Item 7a)

7a. ☐ This Supplemental Information Disclosure Statement under 37 C.F.R. §1.97(f) supplements the Information Disclosure Statement filed on . A bona fide attempt was made to comply with 37 C.F.R. §1.98, but inadvertent omissions were made. These omissions have been corrected herein. Accordingly, additional time is requested so that this Supplemental Information Disclosure Statement can be considered as if properly filed on .

8. ☐ In accordance with 37 C.F.R. §1.98, a concise explanation of what is presently understood to be the relevance of each non-English language publication is:

(Check Item 8a, 8b, or 8c)

8a. ☐ satisfied because all non-English language publications were cited on the enclosed English language copy of the PCT International Search Report or the search report from a counterpart foreign application indicating the degree of relevance found by the foreign office.

8b. ☐ set forth in the application.

8c. ☐ enclosed as an attachment hereto.

9. ☒ The Commissioner is authorized to charge any additional fee required or credit any overpayment for this Information Disclosure Statement and/or Petition to Jones Day Deposit Account No. 50-3013.

10. ☒ No admission is made that the information cited in this Statement is, or is considered to be, material to patentability nor a representation that a search has been made (other than a search report of a foreign counterpart application or PCT International Search Report if submitted herewith). 37 C.F.R. §§1.97(g) and (h).

Respectfully submitted,

Date: July 2, 2004

56,056

David Pauling for
Nikolaos C. George (Reg. No. 39,201)
(Reg. No.)
JONES DAY
222 East 41st Street
New York, New York 10017-6702
(212) 326-3939

LIST OF REFERENCES CITED BY APPLICANT (Use several sheets if necessary)	ATTY DOCKET NO. 11068-014-999	APPLICATION NO 10/612,604
	APPLICANT Huang *et al.*	
	FILING DATE July 1, 2003	GROUP 1648

U.S. PATENT DOCUMENTS

*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	C01	5,631,128	5/97	Kozal *et al.*			
	C02	5,650,268	7/97	Kozal *et al.*			
	C03	5,917,033	6/99	Modak *et al.*			
	C04	6,124,327	9/00	Silverman			
	C05	6,653,081	11/03	Whitcomb			
	C06	20040067487	4/04	Whitcomb			

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION YES	TRANSLATION NO
	C07	WO99/67427	6/99	PCT				
	C08	WO99/61658	12/99	PCT				
	C09	WO02/22781	9/01	PCT				
	C10	International Search Report of PCT/ US99/14486	6/99	PCT				
	C11	International Search Report of PCT/US01/28736	5/02	PCT				
	C12	International Search Report of PCT/US99/11629	9/99	PCT				
	C13	International Search Report of PCT/US01/18882	10/01	PCT				
	C14	Copy of International Search Report PCT/US03/21024	5/04	PCT				

OTHER REFERENCES *(Including Author, Title, Date, Pertinent Pages, Etc.)*

	C15	Ahluwalia, G. S., *et al.* (1996) "2', 3'-Didehydro-3[1]-deoxythymidine: Regulation of its Metabolic Activation by Modulators of Thymidine-5'-triphosphate Biosynthesis" *Mol. Pharm.* 50: 160-165
	C16	Appelt, *et al.*, 1991 "Design of Enzyme Inhibitors Using Iterative Protein Crystallographic Analysis," J. Med. Chem. 34: 1925-1934
	C17	Arnold E., *et al.* (1995) "Structures of DNA and RNA Polymerases and Their Interactions with Nucleic Acid Substrates", Curr Opin Struct Biol 5:27-38;
	C18	Back, KT, et al, (1996) "Reduce Replication of 3TC-Resistant HIV-1 Variants in Primary Cells Due to a Processivity Defect of the Reverse Transcriptase Enzyme", *EMBO* 15: 4040-4049
	C19	Balzarini J, (1998) "A Novel Mutation (F227L) Arises in the Reverse Transcriptase of Human Immunodeficiency Virus Type 1 on Dose-Escalating Treatment of HIV Type 1-Infected Cell Cultures With the Nonnucleoside Reverse Trascriptase Inhibitor Thiocarboxanilide UC-781" AIDS Res. Human, 14(3):255-260

	C20	Balzarini J, *et al.* (1997) "Zidovudine-Resistant Human Presence Immunodeficiency Virus Type 1 Strains Subcultured in the of Both Lamivudine and Quinoxaline HBY 097 Retain Marked Sensitivity to HBY 097 but not to Lamivudine" J of Infect Dis, 176:1392-1397
	C21	Balzarini J., *et al.*, (1992) "HIV-1-Specific Reverse Transcriptase Inhibitors Show Differential Activity Against HIV1 Mutant Strains Containing Different Amino Acid Substitutions in the Reverse Transcriptase", Virology 192:246-253
	C22	Barnes WM, (1994) "PCRAmplication of up to 35-kb DNA with High Fidelity and High Yeild from I. Bacteriophage Templates" *PNAS* 91:2216-2220
	C23	Bartenschlager R, et al, (1994) "Kinetic and Structural Analyses of Hepatitis C Virus Polyprotein Processing", J. *Virol.* 68:5045-5055
	C24	Boucher CAB, et al, (1993) "High-Level Resistance to (-) Enantiomeric 2'-Deoxy-3'-Thiacytidine In Vitro is Due to One Amino Acid Substitution in the Catalytic Site of Human Immunodeficiency Virus Type 1 Reverse Transcriptase", Antimicrob Agents Chemother, 37:2231-2234
	C25	Boucher CAB, et al, (1990) "Zidovudine sensitivity of human immunodeficiency viruses from high-risk, symptom-free individuals during therapy", Lancet 336:585-590
	C26	Boyer, *et al.*, "Analysis of Nonnucleoside Drug-Resistant Variants of Human Immunodeficiency Virus Type 1 Reverse Transcriptase," J. Virol., 67(4):2412-2420 (1993).
	C27	Cheeseman S.H., *et al.* (1995) "Phase I/II Evaluation of Defic Nevirapine Alone and in Combination with Zidvudine for Infection with Human Immunodeficiency Virus", J Acquir Immune Syndr 8:141-151
	C28	Coffin JM, (1995) "HIV Population Dynamics in Vivo: Implications for Genetic Variation, Pathogenesis, and Therapy", Science 267:483-489
	C29	Craig C and Moyle G, (1997) "The development of resistance of HIV-1 to zalcitabine", AIDS 11:271-279.
	C30	Croteau G. et al (1997) "Impaired Fitness of Human Immunodeficiency Virus Type 1 Variants with High-Level Resistance to Protease Inhibitors" J *Virol* 71:1089-1096
	C31	D'Aquilla R.T. (1994) "Molecular Pathogenesis and Laboratory Monitoring", Clin Lab Med 14:393-423
	C32	De Clercq E, (1997) "Development of Resistance of Human the 4); Immunodeficiency Virus (HIV) to Anti-HIV Agents: How to Prevent Problem" Intnl of Antimicro Agnts, 9:21-36
	C33	De Clerq E, (1992) "HIV Inhibitors Targeted at the Revest Transcriptase", AIDS Res. *Hum* Retrovin.8:119-134
	C34	DeJong, M.D., *et al.* (1994) "Alternating Nevirapine and Infected Zidovudine Treatment of Human Immunodeficiency Virus Type 1Persons Does Not Prolong Nevirapine Activity", J Infect Dis 169:1346-1350
	C35	DeJong MD, et al, (1996) "Host-parasite Dynamics and Outgrowth of Virus Containing a Single K7OR Amino Acid Change in Reverse Transcriptase are Responsible for the Loss of Human Immunodeficiency Virus Type 1 RNA Load Suppression by Zidovudine", PNAS 93:5501-5506
	C36	Descamps *et al.*, 1997 "Susceptibility of Human Immunodeficiency Virus Type 1 Group 0 Isolates to Antiretroviral Agents: In Vitro Phenotypic and Genotypic Analyses," Journal of Virology 71(11): 8893-8898.
	C37	De Antoni A., *et al.* Mutations in a pol gene of human immunodeficiency virus type 1 in infected patients receiving didanosine and hydroxyurea combination therapy. *J. Infect Dis.* (1997) OCT.; 176(4): 899-903
	C38	Doyon L, et al, (1996) "Second Locus Involved in Human Immunodeficiency Virus Type 1 Resistance to Protease Inhibitors", *J Virol* 70:3763-3769
	C39	Dueweke, T.J., *et al.* (1993) "A Mutation in Reverse to Other Transcriptase of Bis (Heteroaryl) Piperzine Resistant Human Immunodeficiency Virus Type 1. That Confers Increased Sensitivity; Nonnucleoside Inhibitors", PNAS 90:4713-4717
	C40	Eastman, P. Scott, *et al.* (1995) Monisotopic Hybridization Assay for Determination of Relative Amounts of Genotypic Human Micro, Immunodeficiency Virus Type 1 Zidovudine Resistance", J Clin 2777-2780
	C41	Fitzgibbon *et al.* Human Immunodeficiency virus type 1 pol gene mutations in an AIDS pateint treated with multiple antiretroviral drugs. Journal of Virology, vol. 67, No. 12 (1993) pp. 7271-7275.
	C42	Frenkel *et al.* Specific, sensitive, and rapid assay for human immunodeficiency virus type 1 pol mutations associated with resistance to zidovudine and didanosine. Journal of Clinical Immunology. vol. 33, No. 2 (1995) pp. 342-347.
	C43	Frost, S.D.W., and McLean, A.R. (1994) "Quasispecies Dynamics and the Emergence of Drug Resistance During Zidovudine Therapy of Hiv Infection", AIDS 8:323-332.
	C44	Gerondelis P, et al, (1999) "The P236L Delavirdine-Resistant Human Immunodeficiency Virus Type 1 Mutant is Replication Defective and Demonstrates Alternations in both RNA 5'-End-and DNA 3',-End-Directed RNase H Activities", *J V irol 73:* 5803-5813
	C45	Goulden MG, et al, (1996) "Selection In Vitro of an HIV-1 Variant Resistant to Both Lamivudine (3TC) and Zidvudine", AIDS 10:101-102.
	C46	Gu Z, et al, (1994) "Identification of Novel Mutations that Confer Drug Resistance In the Human Immunodeficiency Virus Polymerase Gene", Leukemia 8(1):166-169.

	C47	Hammond, *et al.*, 1998 "Mutations in Retroviral Genes Associated with Drug Resistance," 36-79.
	C48	Harrigan PR, et al, (1998) "Relative Republication Fitness of Zidovudine-Resistant Human Immunodeficiency Virus Type 1 Isolates In Vitro",J Virol. 72:3773-3778
	C49	Ho DD, et al, (1994) "Characterization of Human Immunodeficiency Virus Type 1 Variants with Increased Resistance to a C2-Symmetric Protease Inhibitor", J Virol 68:2016-2020
	C50	Holodniy, Mark, *et al.* (1995) "Determination of Human Immunodefiency Virus RNA In Plasma and Cellular Viral DNA Genotypic Zidovudine Resistance Combination Therapy", J Virol, 3510-3516
	C51	Hazuda, *et al.*, 2000 "Inhibitors of Strand Transfer That Prevent Integration and Inhibit HIV-1 Replication in Cells," Science 287: 646-650.
	C52	Iversen *et al.* "Multidrug-resistant immunodeficiency virus type 1 strains resulting from combination antiretroviral therapy," Journal of Virology. vol. 70, No. 2 (1996) pp. 1086-1090.
	C53	Kellam, P., *et al.* (1994) "Zidovudine Treatment Results in the Selection of Human Immunodeficiency Virus Type 1 Variants Whose Genotypes Confer Increasing Levels of Drug Resistance", J Gen Virol 75:341-351.
	C54	Kim EE, et al, (1995) "Crystal Structure of HIV-1 Protease in Complex with VX-478, a Potent and Orally Bioavailable Inhibitor of the Enzyme", J Am Chem Soc. 117: 1181-1182
	C55	Kleim, J., *et al.* (1997) "In vitro Selection for Different Mutational Patterns in the HIV-1 Reverse Transcriptase Using High and Low Selective Pressure of the Nonnucleoside Reverse Transcriptase inhibitor HBY 097" *Virology.* 231: 112-118
	C56	Kosalaraksa P, et al, (1999) "Comparative Fitness of Multi-Dideoxynucleoside-Resistant Human Immunodeficiency Virus Type 1 (HIV-1) in an In Vitro Competitive HIV-1 Replication Assay", J Virol 73:5356-5363.
	C57	Krebs, R., *et al.* 1997 "Single-Step Kinetics of HIV-1 Reverse Transcriptase Mutants Responsible for Virus Resistance to Nucleoside Inhibitors Responsible for Virus Resistance to Nucleoside Inhibitors Zidovudine and 3-TC" *Biochemistry* 36: 10292-10300
	C58	Kuritzkes D.R. Clinical significance of drug resistance in HIV-1 infection. AIDS (1996) vol. 10, S27-S31.
	C59	Larder BA, (1992) "3'-Azido-3'-Deoxythymidine Resistance Suppressed by a Mutation Conferring Human Immunodeficiency Virus Type 1 Resistance to Nonnucleoside Reverse Transcriptase Inhibitors", Antimicrob Agents Chemother 36: 2664-2669.
	C60	Larder BA, et al, (1991) "Zidovudine resistance predicted by direct detection of mutations in DNA from HIV-infected lymphocytes", AIDS 5:137-144.
	C61	Larder BA, et al, (1995) "Potential Mechanism for Sustained Antiretroviral Efficacy ofAZT-3TC Combination Therapy", Science 269:696-699.
	C62	Lieven Stuyver, *et al.* (1997) "Line Probe Assay For Rapid Detection Of Drug Selected Mutations In The Human Immunodefiency Virus Type 1 Reverse Transcriptase Gene", Antimicro Aaen and Chemother, 284-291
	C63	Lin PF, et al, (1994) "Genotypic and Phenotypic Analysis of Human Immunodeficiency Virus Type 1 Isolates from Patients on Prolonged Stavudine Therapy", J Infect Disease 170:1157-1164.
	C64	Lopez-Galindez C, et al, (1991) "Characterization of genetic variation and 3'-azido-3'-deoxythymidine-resistance mutations of human immunodeficiency virus by the Rnase A mismatch cleavage method", PNAS 88:4280-4284 (Exhibit 36).
	C65	Mammamo F, et al, (1998) "Resistance-Associated Loss of Viral Fitness in Human Immunodeficiency Virus Type 1: Phenotypis Analysis of Protease and gag Coevoluation inProtease Inhibitor-Treated Patients", J Wrol 72:7632-7637
	C66	Maschera B, et al, (1996) "Mutations in the Viral Protease that Confer Resistance to Saquinavir Increase the Dissociation Rate Constant of the Protease-Saquinavir Complex",) Bio Chem 271:33231-33235.
	C67	Mayers DL, et al, (1992) "Characterization of HIV Isolates Arising After Prolonged Zidovudine Therapy", J Acq Imm Def Synd 5:749-759
	C68	Moyle GJ (1996) "Use of Viral Resistance Patterns to Antiretroviral Drugs in Optimising Selection of Drug Combinations and Sequences", Drugs 52:168-185
	C69	Mohri, H., *et al.* (1993) "Quantitation of Zidovudine Resistant Human Immunodeficiency Virus Type 1 in the Blood of Treated and Untreated Patients", PNAS 90:25-29
	C70	Mulligan RC and Berg P, (1980) "Expression of a Bacterial Gene in Mammalian Cells", Science 209:1422-11427
	C71	Nájera, I., *et al.* (1994) "Natural Occurrence of Drug Resistance Mutations in the Reverse Transcriptase of Human Immunodeficiency Virus Type 1 Isolates", Aids Res Hum Retroviruses 10:1479-1488
	C72	Nájera, I., *et al.* (1995) "pol Gene Quasispecies of Human Immunodeficiency Virus: Mutations Associated with Drug Resistance in virus from Patients Undergoing No Drug Therapy", J Virol 69:23-31
	C73	Nunberg, J.H., *et al.* (1990) "Viral Resistance to Human Immunodeficiency Virus Type 1-Specific Pyridinone Reverse Transcriptase Inhibitors", J Virol 65:4887-4892

	C74	Pelemans H, *et al.* (1997) "Characteristics of the Pro225His Mutation in Human Immunodeficiency Virus Type 1 (HIV-1) Reverse Transcriptase That Appears Under Selective Pressure of Dose Escalating Quinoxaline Treatment of HIV-1" J. Viro, 71(11) :8195-8203
	C75	Richman, D.D. *et al.* (1994) "Nevirapine Resistance Mutations of Human Immunodeficiency Virus Type 1 Selected during Therapy", J Virol 68:1660-1666
	C76	Richman, D.D. *et al.* (1991) "Human Immunodeficiency Virus Type 1 Mutants Resistant to Nonnucleoside Inhibitors of Reverse Transcriptase Arise in Tissue Culture", PNAS 88:11241-11245
	C77	Sanger, *et al.* (1977) "DNA Sequencing with Chain-terminating Inhibitors", PNAS 88: 11241-245.
	C78	Sakar, G. and Sommer, S.S. (1990) "The "Megaprimer" Method of Site-Directed Mutagenesis" Biotech, 8(4):404-407
	C79	Shafer RW, et al, (1994) "Combination Therapy with Zidovudine and Didanosine Selects for Drug-Resistant Human Immunodeficiency Virus Type 1 Strains with Unique Patterns of pol Gene Mutations", *J Infect Disease* 169:722-729
	C80	Shirasaka T, et al, (1995) "Emergence of Human Immunodeficiency Virus Type 1 Variants with Resistance to Multiple Deoxynucleosides in Patients Receiving Therapy with Dideoxynucleosides", *PNAS* 92:2398-2402
	C81	Southern, *et al.* (1982) "Transformation of Mammalian Cells to Antibotic Resistance with a Bacterial Gene Under Control of the SV40 Early Region Promoter", Appl. Genet 1:327-341
	C82	Strair RK, *et al.* (1993) "Recombinant Retroviral Systems For the Analysis of Drug Resistant HIV" Nucl Acds Res, 21(20): 4836-4842
	C83	Sugden B, et al, (1985)"A Vector that Replicates as a Plasmid and can be Efficiently Selected in B-Lymphoblasts Transformed by Epstein-Barr Virus", Mol Cell Bio 5:410-413.
	C84	Tisdale M, et al, (1993) "Rapid In Vitro Selection of Human Immunodeficiency Virus Type 1 Resistant to 3'-Thiacytidine Inhibitors due to a Mutation in the YMDD Region of Reverse Transcriptase", *PNAS* 90:5653-5656.
	C85	Vacca JP, et al, (1994) "L-735,524: An Orally Bioavailable Human Immunodeficiency Virus Type 1 Protease Inhibitor", PNAS 91:4096-4100.
	C86	Villahermosa, ML, *et al.* "Evaluations of mixtures of wild-type HIV-1 and HIV-1 with resistance point mutations against reverse transcriptase inhibitors" *Antiviral Ther.* (1998); 3(4):221-227
	C87	Zennou V, (1998) "Loss of Viral Fitness Associated with Multiple Gag and Gag-Pol Processing Defects in Human Immunodeficiency Virus Type 1 Variants Selected for Resistance to Protease Inhibitors In Vivo", J. Virol., 72:3300-3306.
	C88	Zhang Y, et al, (1997) "Drug Resistance During Indinavir Therapy is Caused by Mutations in the Protease Gene and in its Gag Substrate Cleavage Sites", J Virol 71:6662-6670.
	C89	Zhang D, et al, (1994) "Resistance to 2',3'-Dideoxycytidine Conferred by a Mutation in Codon 65 of the Human Immunodeficiency Virus Type 1 Reverse Transcriptase", *Antimicrob Agents Chemother* 38:282-287

EXAMINER	**DATE CONSIDERED**

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with **MPEP 609**; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.